Homocysteine and ADMA - Emerging risk factors for cardiovascular disease?

Blood Pressure

Volumn 11, Issue 4, 2002, Pages 197-200

  Hedner, Thomas ^a   Himmelmann, Anders ^a   Hansson, Lennart ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CYSTATHIONINE BETA SYNTHASE; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHIONINE SYNTHASE; MEVINOLIN; N(G),N(G) DIMETHYLARGININE; PLACEBO; ARGININE; DRUG DERIVATIVE; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE;

ADRENERGIC ACTIVITY; AMINO ACID BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE ASSOCIATION; EDITORIAL; GENETIC POLYMORPHISM; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; PATHOGENESIS; PRIORITY JOURNAL; STROKE; BLOOD; GENETICS; NOTE; PREDICTION AND FORECASTING; RISK FACTOR;

ARGININE; CARDIOVASCULAR DISEASES; HOMOCYSTEINE; HUMANS; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 0036381268     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/08037050213763     Document Type: Editorial

References (30)

1. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31-62.
2. Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. In J Epidemiol 2002; 31: 59-70.
3. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J. Cardiovasc Risk 1998; 5: 229-232.
4. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusef S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999; 131: 363-375.
5. Wocial B, Bernet H, Kostrubiec M, Kuczynska K, Kuch-Wocial A, Nieweglowska N. Homocysteine adrenergic activity and left ventricular mass in patients with essential hypertension. Blood Pressure 2002; 11: 201-205.
6. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969; 56: 111-128.
7. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.
8. Ridker PM, Shih J, Cook TJ, Clearfield M, Downs JR, Pradhan AD, Weis SE, Gotto AM Jr; Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Investigators. Plasma homocysteine concentration, statin therapy, and the risk first acute coronary events. Circulation 2002; 105: 1776-1779.
9. Zhang G, Dai C. Correlation analysis between plasma homocysteine level and polymorphism of homocysteine metabolism related enzymes in ischemic cerebrovascular or cardiovascular diseases (Chinese). Zhonghua Xue Ye Xue Za Zhi 2002; 23: 126-129.
10. Rolland PH, Friggi A, Barlatier A et al. Hyperhomocysteinemia-induced vascular damage in the minipig. Circulation 1995; 91: 1161-1174.
11. Woo KS, Chook P, Lolin YI, et al. Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 2542-2544.
12. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-1376.
13. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia, enhances platelet aggregation, thromboxande biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J 1997; 11: 1157-1168.
14. Stamler JS, Osborne JA, Jaraki O et al. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 303-318.
15. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein (a) to fibrin: a potential link between thrombosis, atherogenesis and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10193-10197.
16. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517-527.
17. De Vriese AS, Verbeke F, Schrijvers BF, Lameire NH. Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure? Kidney Int 2002; 61: 1199-1209.
18. Mangoni AA, Jackson SH. Homocysteine and cardiovascular disease: Current evidence and future prospects. Am J Med 2002; 112: 556-565.
19. Böger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frölich JC. Biochemical evidence of impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068-2074.
20. Böger RH, Bode-Böger SM, Szuba A et al. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847.
21. G -dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor, in dialysis patients. J Am Soc Nephrol 1997; 8: 1437-1442.
22. Kielstein JT, Böger RH, Bode-Böger SM et al. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Neprhol 1999; 10: 594-600.
23. Miyazaki H, Matsuoka H, Cooke JP et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999; 99: 1141-1146.
24. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependnet methyltransferases. Circ Res 2000; 87: 99-105.
25. Boger RH, Bode-Boger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentrations of asymmetric dimethylarginine, and endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hyperholesterolemia. Arterioscler Throm Vasc Biol 2000; 20: 1557-1564.
26. Boger RH, Lentz SR, Bode-Boger SM, Knapp HR, Haynes WG. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e) inaemia in humans. Clin Sci (Lond) 2001: 100: 161-167.
27. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575.
28. Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 2001; 358: 2096-2097.
29. Surdacki A, Nowicki M, Sandmann J et al. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652-658.
30. Faraci FM, Brian JE, Heistad DD. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol 1995; 269; H1522-1527.